Treatment of sulfonylurea and insulin overdose
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The most common toxicity associated with sulfonylureas and insulin is hypoglycaemia. The article reviews existing evidence to better guide hypoglycaemia management. Sulfonylureas and insulin have narrow therapeutic indices. Small doses can cause hypoglycaemia, which may be delayed and persistent. All children and adults with intentional overdoses need to be referred for medical assessment and treatment. Unintentional supratherapeutic ingestions can be initially managed at home but if symptomatic or if there is persistent hypoglycaemia require medical referral. Patients often require intensive care and prolonged observation periods. Blood glucose concentrations should be assessed frequently. Asymptomatic children with unintentional sulfonylurea ingestions should be observed for 12 h, except if this would lead to discharge at night when they should be kept until the morning. Prophylactic intravenous dextrose is not recommended. The goal of therapy is to restore and maintain euglycaemia for the duration of the drug's toxic effect. Enteral feeding is recommended in patients who are alert and able to tolerate oral intake. Once insulin or sulfonylurea‐induced hypoglycaemia has developed, it should be initially treated with an intravenous dextrose bolus. Following this the mainstay of therapy for insulin‐induced hypoglycaemia is intravenous dextrose infusion to maintain the blood glucose concentration between 5.5 and 11 mmol l–1. After sulfonylurea‐induced hypoglycaemia is initially corrected with intravenous dextrose, the main treatment is octreotide which is administered to prevent insulin secretion and maintain euglycaemia. The observation period varies depending on drug, product formulation and dose. A general guideline is to observe for 12 h after discontinuation of intravenous dextrose and, if applicable, octreotide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triggering and amplifying pathways of regulation of insulin secretion by glucose.
Henquin, J. C. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1751 · Cited by 1,201
Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses.
Boyle, P. J., Justice, K., Krentz, A. J., Nagy, R. J., & Schade, D. S. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.3.8445035 · Cited by 125
Cited by
A systematic review on insulin overdose cases: Clinical course, complications and treatment options
Johansen, N. J., & Christensen, M. B. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12957 · Cited by 49
Management of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia
Goncalves, M. D., & Farooki, A. (2022) · Integrative Cancer Therapies · doi:10.1177/15347354211073163 · Cited by 37
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Literature Review: Drug and Alcohol-Induced Hypoglycaemia
Kalaria, T., Ko, Y. L., & Issuree, K. K. J. (2021) · Journal of Laboratory and Precision Medicine · doi:10.21037/jlpm-21-16 · Cited by 17
“The clinical team should be wary of recurrent hypoglycaemia after correction of the presenting episode of hypoglycaemia, especially with longer-acting sulphonylureas and long-acting insulins (15).”
BackgroundInfluential
Metadata
- Authors
- Klein‐Schwartz, W., Stassinos, G. L., & Isbister, G. K.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2016-01-06
- Volume
- 81
- Issue
- 3
- Pages
- 496-504
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2142028920
- Cited by
- 71
- References
- 2
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of sulfonylurea and insulin overdose. https://app.cochat.ai/papers/10.1111/bcp.12822
- The paper
- Klein‐Schwartz, W., Stassinos, G. L., & Isbister, G. K. (2016). Treatment of sulfonylurea and insulin overdose. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.12822
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.